Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 12
2003 20
2004 16
2005 29
2006 44
2007 44
2008 49
2009 69
2010 84
2011 97
2012 96
2013 125
2014 136
2015 168
2016 173
2017 188
2018 199
2019 252
2020 326
2021 378
2022 397
2023 332
2024 366
2025 5

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

3,251 results

Results by year

Filters applied: . Clear all
Page 1
Tislelizumab Plus Chemotherapy vs Chemotherapy Alone as First-line Treatment for Advanced Squamous Non-Small-Cell Lung Cancer: A Phase 3 Randomized Clinical Trial.
Wang J, Lu S, Yu X, Hu Y, Sun Y, Wang Z, Zhao J, Yu Y, Hu C, Yang K, Feng G, Ying K, Zhuang W, Zhou J, Wu J, Leaw SJ, Zhang J, Lin X, Liang L, Yang N. Wang J, et al. Among authors: zhao j. JAMA Oncol. 2021 May 1;7(5):709-717. doi: 10.1001/jamaoncol.2021.0366. JAMA Oncol. 2021. PMID: 33792623 Free PMC article. Clinical Trial.
Adebrelimab or placebo plus carboplatin and etoposide as first-line treatment for extensive-stage small-cell lung cancer (CAPSTONE-1): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.
Wang J, Zhou C, Yao W, Wang Q, Min X, Chen G, Xu X, Li X, Xu F, Fang Y, Yang R, Yu G, Gong Y, Zhao J, Fan Y, Liu Q, Cao L, Yao Y, Liu Y, Li X, Wu J, He Z, Lu K, Jiang L, Hu C, Zhao W, Zhang B, Shi W, Zhang X, Cheng Y; CAPSTONE-1 Study Group. Wang J, et al. Among authors: zhao j. Lancet Oncol. 2022 Jun;23(6):739-747. doi: 10.1016/S1470-2045(22)00224-8. Epub 2022 May 13. Lancet Oncol. 2022. PMID: 35576956 Clinical Trial.
KLRG1+ Effector CD8+ T Cells Lose KLRG1, Differentiate into All Memory T Cell Lineages, and Convey Enhanced Protective Immunity.
Herndler-Brandstetter D, Ishigame H, Shinnakasu R, Plajer V, Stecher C, Zhao J, Lietzenmayer M, Kroehling L, Takumi A, Kometani K, Inoue T, Kluger Y, Kaech SM, Kurosaki T, Okada T, Flavell RA. Herndler-Brandstetter D, et al. Among authors: zhao j. Immunity. 2018 Apr 17;48(4):716-729.e8. doi: 10.1016/j.immuni.2018.03.015. Epub 2018 Apr 3. Immunity. 2018. PMID: 29625895 Free PMC article.
Mechanically Interlocked Vitrimers.
Zhao J, Zhang Z, Cheng L, Bai R, Zhao D, Wang Y, Yu W, Yan X. Zhao J, et al. J Am Chem Soc. 2022 Jan 19;144(2):872-882. doi: 10.1021/jacs.1c10427. Epub 2021 Dec 21. J Am Chem Soc. 2022. PMID: 34932330
Tepotinib plus gefitinib in patients with EGFR-mutant non-small-cell lung cancer with MET overexpression or MET amplification and acquired resistance to previous EGFR inhibitor (INSIGHT study): an open-label, phase 1b/2, multicentre, randomised trial.
Wu YL, Cheng Y, Zhou J, Lu S, Zhang Y, Zhao J, Kim DW, Soo RA, Kim SW, Pan H, Chen YM, Chian CF, Liu X, Tan DSW, Bruns R, Straub J, Johne A, Scheele J, Park K, Yang JC; INSIGHT Investigators. Wu YL, et al. Among authors: zhao j. Lancet Respir Med. 2020 Nov;8(11):1132-1143. doi: 10.1016/S2213-2600(20)30154-5. Epub 2020 May 29. Lancet Respir Med. 2020. PMID: 32479794 Clinical Trial.
Viral pseudoenzymes in infection and immunity.
Wang TY, Zhao J, Savas AC, Zhang S, Feng P. Wang TY, et al. Among authors: zhao j. FEBS J. 2020 Oct;287(19):4300-4309. doi: 10.1111/febs.15545. Epub 2020 Sep 17. FEBS J. 2020. PMID: 32889786 Free PMC article. Review.
3,251 results